Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rigel Pharmaceuticals, Inc.

Latest From Rigel Pharmaceuticals, Inc.

Lupin’s Confidence Over Mirabegron Relaunch Doesn’t Convince Analyst

While Lupin is “truly excited with the potential” ahead, the uncertainty around upcoming product launches paints a different financial picture.

Generic Drugs Launches

Lupin CEO Highlights Structural Support For Generics Pricing, Sees gMyrbetriq Relaunch

Lupin’s CEO spoke of US drug shortages having led to recognition of the need for structural and regulatory support for viable pricing of generic drugs. She was also optimistic on the relaunch of a Myrbetriq generic after Astellas obtained a temporary restraining order against Lupin and Zydus just a few days post an at-risk launch by the latter two companies

Commercial Sales & Earnings

Dr Reddy’s Enters US With Second Oracea Generic

Dr Reddy’s has launched the second US rival to Oracea, shortly after Lupin introduced the first generic doxycycline 40mg capsules following a favorable district court ruling.

Launches Generic Drugs

Lupin Enters Canadian Biosimilars Market With Etanercept

Lupin has pushed into the Canadian biosimilars market with the launch of its Rymti rival to Amgen’s Enbrel. The launch is taking place via Lupin’s local partner Sandoz.

Biosimilars Launches
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals